Caribou Biosciences (NASDAQ:CRBU) Downgraded by Leerink Partners to Hold

Key Points

• Leerink Partners downgraded Caribou Biosciences to “Hold” from “Outperform” and set a $1.00 price target, implying roughly 62% upside from the reported $0.62 share price.
• Analyst sentiment remains mixed: RBC also cut its rating to “Sector Perform” with a $1 target, while the broader consensus is still “Moderate Buy” with a $5.50 target.
• Caribou is evaluating strategic alternatives, including a potential sale, while discontinuing two CAR-T programs and reducing its workforce to conserve cash—steps that substantially narrow its development pipeline.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) was downgraded by Leerink Partners from an "outperform" rating to a "hold" rating in a research report issued on Wednesday, Marketbeat Ratings reports. They presently have a $1.00 target price on the stock. Leerink Partners' price objective would indicate a potential upside of 61.97% from the stock's current price.

A number of other brokerages also recently commented on CRBU. Brookline Capital Markets reaffirmed a "hold" rating on shares of Caribou Biosciences in a research report on Wednesday. Wall Street Zen downgraded Caribou Biosciences from a "hold" rating to a "sell" rating in a research report on Saturday, September 19th. Weiss Ratings reissued a "sell (d-)" rating on shares of Caribou Biosciences in a research note on Friday, July 17th. Bank of America lowered their price target on Caribou Biosciences from $6.00 to $5.00 and set a "buy" rating for the company in a report on Friday, August 14th. Finally, Royal Bank Of Canada downgraded shares of Caribou Biosciences from an "outperform" rating to a "sector perform" rating and set a $1.00 price objective for the company. in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, Caribou Biosciences currently has a consensus rating of "Moderate Buy" and a consensus price target of $5.50.

Caribou Biosciences Stock Performance

CRBU stock opened at $0.62 on Wednesday. The stock has a market capitalization of $66.19 million, a P/E ratio of -0.57 and a beta of 2.31. Caribou Biosciences has a one year low of $0.55 and a one year high of $3.54. The company has a 50 day moving average price of $1.45 and a two-hundred day moving average price of $1.75.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.08. Caribou Biosciences had a negative return on equity of 89.11% and a negative net margin of 1,030.42%.The company had revenue of $1.50 million during the quarter, compared to the consensus estimate of $2.28 million. Research analysts forecast that Caribou Biosciences will post -0.88 earnings per share for the current fiscal year.

Institutional Trading of Caribou Biosciences

A number of institutional investors and hedge funds have recently made changes to their positions in CRBU. CTC Alternative Strategies Ltd. acquired a new position in shares of Caribou Biosciences in the 1st quarter valued at approximately $29,000. Westmount Partners LLC acquired a new stake in shares of Caribou Biosciences during the first quarter worth approximately $37,000. Next Capital Management LLC acquired a new stake in shares of Caribou Biosciences during the second quarter worth approximately $35,000. The Manufacturers Life Insurance Company bought a new stake in shares of Caribou Biosciences in the second quarter worth $41,000. Finally, Spark Investment Management LLC bought a new stake in shares of Caribou Biosciences in the second quarter worth $42,000. 77.51% of the stock is currently owned by institutional investors and hedge funds.

Key Caribou Biosciences News

Here are the key news stories impacting Caribou Biosciences this week:

• Positive Sentiment: Caribou will evaluate strategic alternatives, including a potential sale or other transaction, with the stated goal of maximizing stockholder value. A transaction could provide value to shareholders despite the company’s reduced pipeline. Caribou Biosciences to Evaluate Strategic Alternatives
• Neutral Sentiment: Brookline Capital Markets reaffirmed its “hold” rating, indicating that the firm sees limited near-term evidence to support either a bullish or bearish change in its outlook.
• Negative Sentiment: The company plans to discontinue its vispa-cel and CB-011 allogeneic CAR-T programs, removing two key clinical development assets and substantially reducing the basis for future growth. Caribou Biosciences To Halt Two CAR-T Programs, Cut Workforce; Shares Plunge
• Negative Sentiment: Caribou also intends to reduce its workforce and conserve cash while it considers strategic options, signaling a narrower operating plan and continued financial pressure. Caribou Biosciences to halt CAR-T programs, explore sale
• Negative Sentiment: RBC downgraded CRBU from “Outperform” to “Sector Perform” and slashed its price target to $1 from $10, while retaining a speculative-risk designation. The steep target reduction reflects materially lower expectations following the program cancellations. RBC downgrades Caribou Biosciences

About Caribou Biosciences

Caribou Biosciences, Inc is a clinical-stage biotechnology company developing genome-edited cell therapies for cancer and other serious diseases. The company uses its proprietary CRISPR-based chRDNA genome-editing platform to engineer immune cells, with an emphasis on allogeneic, or “off-the-shelf,” CAR-T therapies designed to target tumors without requiring cells to be collected from each individual patient.

Caribou's research and development programs have focused primarily on hematologic malignancies, including investigational CAR-T candidates directed at targets such as CD19 and BCMA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.